{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:37:19Z","timestamp":1786664239308,"version":"build-2736575974"},"reference-count":12,"publisher":"SAGE Publications","issue":"4-5","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Siponimod-related lymphopenia in real-world clinical practice has implications for dose adjustment and infection risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To characterise siponimod-related lymphopenia in people with secondary progressive multiple sclerosis (pwSPMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a retrospective cohort of 188 pwSPMS. The development of grade 4 lymphopenia was interrogated with Kaplan\u2013Meier survival analysis and binary logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Lymphopenia develops soon after commencing siponimod. In total, 15 (8.5%) of 176 experienced grade 4 lymphopenia at 1 month after initiation. There were no clinically significant associations between patient characteristics and development of grade 4 lymphopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Grade 4 lymphopenia can occur soon after siponimod initiation and cannot be predicted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585231225711","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T04:57:25Z","timestamp":1707281845000},"page":"600-604","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5845-9429","authenticated-orcid":false,"given":"Christopher GS","family":"Gilmartin","sequence":"first","affiliation":[{"name":"Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University of Nottingham, Nottingham, UK"},{"name":"Clinical Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Hoyle","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9271-346X","authenticated-orcid":false,"given":"Afagh","family":"Garjani","sequence":"additional","affiliation":[{"name":"Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University of Nottingham, Nottingham, UK"},{"name":"Clinical Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Dixon","sequence":"additional","affiliation":[{"name":"Clinical Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Jos","sequence":"additional","affiliation":[{"name":"University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Paling","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace","family":"Brownlee","sequence":"additional","affiliation":[{"name":"Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK"},{"name":"National Institute for Health and Care Research (NIHR) University College London Hospitals Biomedical Research Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Tench","sequence":"additional","affiliation":[{"name":"Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University of Nottingham, Nottingham, UK"},{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-0672","authenticated-orcid":false,"given":"Nikos","family":"Evangelou","sequence":"additional","affiliation":[{"name":"Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University of Nottingham, Nottingham, UK"},{"name":"Clinical Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"European Medicines Agency (EMA). Mayzent https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mayzent (2019 accessed 11 September 2023)."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30475-6"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2178898"},{"key":"e_1_3_2_5_2","unstructured":"Jones. NDA 209884 Mayzent (siponimod). Center for Drug Evaluation and Research 2017 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/209884Orig1s000MedR.pdf"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2020.05.016"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(19960315)26:1<8::AID-CYTO2>3.0.CO;2-E"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000567"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001049"},{"key":"e_1_3_2_10_2","unstructured":"Treatment for relapsing MS MAYZENT (siponimod) https:\/\/www.mayzent.com\/ (accessed 21 September 2023)."},{"key":"e_1_3_2_11_2","unstructured":"Relapsing-remitting multiple sclerosis I GILENYA https:\/\/www.gilenya.com\/ (accessed 21 September 2023)."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Sansoni P Cossarizza A Brianti V et al. Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 1993; 82(9): 2767\u20132773 https:\/\/www-sciencedirect-com.nottingham.idm.oclc.org\/science\/article\/pii\/S0006497120819259?via%3Dihub (accessed 13 April 2023).","DOI":"10.1182\/blood.V82.9.2767.bloodjournal8292767"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Aiello A Farzaneh F Candore G et al. Immunosenescence and its hallmarks: How to oppose aging strategically? A review of potential options for therapeutic intervention. Front Immunol 2019; 10: 2247 https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2019.02247 (accessed 5 April 2023).","DOI":"10.3389\/fimmu.2019.02247"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585231225711","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585231225711","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585231225711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:14:10Z","timestamp":1777695250000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585231225711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":12,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1177\/13524585231225711"],"URL":"https:\/\/doi.org\/10.1177\/13524585231225711","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}